Department of Pathology and Molecular Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.
Department of Cardiothoracic Anesthesiology, Anesthesiology Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
Chest. 2024 Aug;166(2):321-338. doi: 10.1016/j.chest.2024.02.049. Epub 2024 Mar 4.
Albumin is used commonly across a wide range of clinical settings to improve hemodynamics, to facilitate fluid removal, and to manage complications of cirrhosis. The International Collaboration for Transfusion Medicine Guidelines developed guidelines for the use of albumin in patients requiring critical care, undergoing cardiovascular surgery, undergoing kidney replacement therapy, or experiencing complications of cirrhosis.
Cochairs oversaw the guideline development process and the panel included researchers, clinicians, methodologists, and a patient representative. The evidence informing this guideline arises from a systematic review of randomized clinical trials and systematic reviews, in which multiple databases were searched (inception through November 23, 2022). The panel reviewed the data and formulated the guideline recommendations using Grading of Recommendations Assessment, Development, and Evaluation methodology. The guidelines were revised after public consultation.
The panel made 14 recommendations on albumin use in adult critical care (three recommendations), pediatric critical care (one recommendation), neonatal critical care (two recommendations), cardiovascular surgery (two recommendations), kidney replacement therapy (one recommendation), and complications of cirrhosis (five recommendations). Of the 14 recommendations, two recommendations had moderate certainty of evidence, five recommendations had low certainty of evidence, and seven recommendations had very low certainty of evidence. Two of the 14 recommendations suggested conditional use of albumin for patients with cirrhosis undergoing large-volume paracentesis or with spontaneous bacterial peritonitis. Twelve of 14 recommendations did not suggest albumin use in a wide variety of clinical situations where albumin commonly is transfused.
Currently, few evidence-based indications support the routine use of albumin in clinical practice to improve patient outcomes. These guidelines provide clinicians with actionable recommendations on the use of albumin.
白蛋白在广泛的临床环境中被广泛用于改善血液动力学、促进液体清除以及管理肝硬化并发症。国际输血医学协作指南为需要重症监护、心血管手术、肾脏替代治疗或经历肝硬化并发症的患者制定了白蛋白使用指南。
联合主席监督了指南制定过程,专家组包括研究人员、临床医生、方法学家和患者代表。该指南的证据来源于对随机临床试验和系统评价的系统评价,其中多个数据库进行了搜索(从开始到 2022 年 11 月 23 日)。专家组审查了数据,并使用推荐评估、制定和评价方法学制定了指南建议。在公开咨询后,指南进行了修订。
专家组就白蛋白在成人重症监护(三项建议)、儿科重症监护(一项建议)、新生儿重症监护(两项建议)、心血管手术(两项建议)、肾脏替代治疗(一项建议)和肝硬化并发症(五项建议)方面的使用提出了 14 项建议。在 14 项建议中,有两项建议的证据确定性为中度,五项建议的证据确定性为低度,七项建议的证据确定性为非常低。14 项建议中的两项建议建议对接受大容量腹腔穿刺或自发性细菌性腹膜炎的肝硬化患者有条件地使用白蛋白。14 项建议中的 12 项建议并不建议在白蛋白广泛输注的各种临床情况下使用白蛋白。
目前,很少有基于证据的适应症支持白蛋白在改善患者预后的常规临床实践中的使用。这些指南为临床医生提供了关于白蛋白使用的可行建议。